Chagas Disease and the London Declaration on Neglected Tropical Diseases

PLoS Neglected Tropical Diseases

Volumn 8, Issue 10, 2014, Pages

  Tarleton, Rick L ^a,b   Gürtler, Ricardo E ^c   Urbina, Julio A ^d   Ramsey, Janine ^e   Viotti, Rodolfo ^f  

^a UNIVERSITY OF GEORGIA   (United States)

^b The Chagas Disease Foundation   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f Hospital Interzonal General de Agudos HIGA Eva Perón   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHAGAS DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ORGANIZATION; HUMAN; INFECTION CONTROL; NEGLECTED DISEASE; NONHUMAN; PUBLIC HEALTH; PUBLIC HEALTH PROBLEM; TREATMENT OUTCOME; TREATMENT PLANNING; TROPICAL DISEASE;

EID: 84920523000     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003219     Document Type: Article

References (35)

1. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR, (2008) The neglected tropical diseases of latin america and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2: e300.
2. Urbina JA, (2010) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 55–68.
3. Marin-Neto JA, Rassi A, JrAvezum A, JrMattos AC, Rassi A, et al. (2009) The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104 Suppl 1: 319–324 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease. Population Health Research Institute. Available: http://clinicaltrials.gov/. Identifier: NCT00123916.
4. Riarte A (2013) TRAENA: Placebo-controlled evaluation of impact of benznidazole treatment on long-term disease progression in adults with chronic Chagas disease. In: Proceedings of the 62nd Annual Meeting of the American Society of Tropical Medicine and Hygiene; November 13–17, 2013; Washington, DC.
5. Torrico F (2013) E1224–Results of proof of concept clinical trial in patients with chronic indeterminate Chagas disease. In: Proceedings of the 62nd Annual Meeting of the American Society of Tropical Medicine and Hygiene; November 13–17, 2013; Washington, DC. Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease. Drugs for Neglected Diseases Initiative. Available: http://clinicaltrials.gov/. Identifier: NCT01489228.
6. Molina I (2012) First clinical trial with posaconazole and benznidazole for the treatment of chronic Chagas disease. In: Proceedings of the XVIII International Congress of Tropical Medicine and Malaria; September 23–27, 2012; Rio de Janeiro, Brazil. Available: http://ictmm2012.ioc.fiocruz.br/program_25_sept.html. Accessed 8 September 2014. Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole (CHAGASAZOL). Hospital Universitari Vall d'Hebron Research Institute. http://clinicaltrials.gov/. Identifier: NCT01162967.
7. A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS). Merck Sharp & Dohme Corp. Available: http://clinicaltrials.gov/. Identifier: NCT01377480. Accessed 8 September 2014.
8. Tarleton RL, (2001) Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31: 549–553.
9. Tarleton RL, (2003) Chagas Disease: a role for autoimmunity? Trends Parasitol 10: 447–451.
10. Viotti R, de Noya BA, Araujo-Jorge T, Grijalva MJ, Guhl F, et al. (2014) Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother 58: 635–639.
11. Wilkinson SR, Bot C, Kelly JM, Hall BS, (2011) Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem 11: 2072–2084.
12. Cencig S, Coltel N, Truyens C, Carlier Y, (2012) Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome(R) in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents 40: 527–532.
13. Diniz Lde F, Urbina JA, de Andrade IM, Mazzeti AL, Martins TA, et al. (2013) Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 7: e2367.
14. Bustamante J, Craft JM, Ketchie SA, Tarleton RL, (2014) Efficacy of alternate and combination drug treatment protocols in cure of Trypanosoma cruzi infection in mice. J Infect Dis 209: 150–162.
15. Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, et al. (2013) Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother 68: 424–437.
16. Kurup SP, Tarleton RL, (2013) Perpetual expression of PAMPs is necessary for optimal immune control and clearance of an otherwise persistent pathogen. Nat Commun 4: 2616.
17. Cecere MC, Vazquez-Prokopec GM, Ceballos LA, Boragno S, Zarate JE, et al. (2013) Improved chemical control of Chagas disease vectors in the dry Chaco region. J Med Entomol 50: 394–403.
18. Gurtler RE, (2009) Sustainability of vector control strategies in the Gran Chaco region: current challenges and possible approaches. Mem Inst Oswaldo Cruz 104 Suppl 1: 52–59.
19. Yadón ZE, Gürtler RE, Tobar F, Medici AC (2007) Decentralization and Management of Communicable Disease Control in Latin America. Buenos Aires: Pan American Health Organization. Available: http://www.paho.org/English/ad/dpc/cd/res-descentralizacion.htm. Accessed 8 September 2014.
20. Picollo MI, Vassena C, Santo Orihuela P, Barrios S, Zaidemberg M, et al. (2005) High resistance to pyrethroid insecticides associated with ineffective field treatments in Triatoma infestans (Hemiptera: Reduviidae) from Northern Argentina. J Med Entomol 42: 637–642.
21. Lardeux F, Depickere S, Duchon S, Chavez T, (2010) Insecticide resistance of Triatoma infestans (Hemiptera, Reduviidae) vector of Chagas disease in Bolivia. Trop Med Int Health 15: 1037–1048.
22. Gurevitz JM, Gaspe MS, Enriquez GF, Vassena CV, Alvarado-Otegui JA, et al. (2012) Unexpected failures to control Chagas Disease vectors with pyrethroid spraying in northern Argentina. J Med Entomol 49: 1379–1386.
23. Levy MZ, Bowman NM, Kawai V, Waller LA, Cornejo del Carpio JG, et al. (2006) Periurban Trypanosoma cruzi-infected Triatoma infestans, Arequipa, Peru. Emerg Infect Dis 12: 1345–1352.
24. Medrano-Mercado N, Ugarte-Fernandez R, Butron V, Uber-Busek S, Guerra HL, et al. (2008) Urban transmission of Chagas disease in Cochabamba, Bolivia. Mem Inst Oswaldo Cruz 103: 423–430.
25. Munoz-Calderon A, Diaz-Bello Z, Valladares B, Noya O, Lopez MC, et al. (2013) Oral transmission of Chagas disease: typing of Trypanosoma cruzi from five outbreaks occurred in Venezuela shows multiclonal and common infections in patients, vectors and reservoirs. Infect Genet Evol 17: 113–122.
26. Shikanai-Yasuda MA, Carvalho NB, (2012) Oral transmission of Chagas disease. Clin Infect Dis 54: 845–852.
27. Rassi A, JrDias JC, Marin-Neto JA, Rassi A, (2009) Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 95: 524–534.
28. Ribeiro I, Sevcsik AM, Alves F, Diap G, Don R, et al. (2009) New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 3: e484.
29. Laucella SA, Perez Mazliah D, Bertocchi G, Alvarez MG, Cooley G, et al. (2009) Changes in Trypanosoma cruzi-specific immune responses following treatment: surrogate markers of treatment efficacy. Clin Infect Dis 49: 1675–1684.
30. Cooley G, Etheridge RD, Boehlke C, Bundy B, Weatherly DB, et al. (2008) High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2: e316.
31. Fernandez-Villegas A, Pinazo MJ, Maranon C, Thomas MC, Posada E, et al. (2011) Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers. BMC Infect Dis 11: 206.
32. Abad-Franch F, Diotaiuti L, Gurgel-Goncalves R, Gurtler RE, (2013) Certifying the interruption of Chagas disease transmission by native vectors: cui bono? Mem Inst Oswaldo Cruz 108: 251–254.
33. Abad-Franch FDL, Gurgel-Gonçalvez R, Gürtler RE, (2014) On bugs and bias: improving Chagas disease control assessment. Mem Inst Oswaldo Cruz 109: 125–130.
34. Reithinger R, Ceballos L, Stariolo R, Davies CR, Gurtler RE, (2006) Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg 74: 766–771.
35. Levy MZ, Quispe-Machaca VR, Ylla-Velasquez JL, Waller LA, Richards JM, et al. Impregnated netting slows infestation by Triatoma infestans. Am J Trop Med Hyg 79: 528–534.